Get notified when SYRE files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SYRE Spyre Therapeutics, Inc. 8-K

Spyre Therapeutics reports Q1 2026 financial results

Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read

Key Changes

  • medium

    Company issued press release announcing first quarter 2026 financial results for period ended March 31, 2026. Actual financial figures are in the attached press release, not in the 8-K filing itself.

    Item 2.02 verify on EDGAR →
  • medium

    This is a routine quarterly earnings announcement filing. Investors should review the full press release (Exhibit 99.1) for revenue, earnings, cash position, and any forward guidance.

    8-K: Earnings verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.

Partner

Trade SYRE commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov Press release (Ex 99.1) on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify